Literature DB >> 20043028

Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application.

Aimee L Jackson1, Peter S Linsley.   

Abstract

Small interfering RNAs (siRNAs) are widely used to study gene function owing to the ease with which they silence target genes, and there is considerable interest in their potential for therapeutic applications. In a remarkably short time since their discovery, siRNAs have entered human clinical trials in various disease areas. However, rapid acceptance of the use of siRNAs has been accompanied by recognition of several hurdles for the technology, including a lack of specificity. Off-target activity can complicate the interpretation of phenotypic effects in gene-silencing experiments and can potentially lead to unwanted toxicities. Here, we describe the types of off-target effects of siRNAs and methods to mitigate them, to help enable effective application of this exciting technology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20043028     DOI: 10.1038/nrd3010

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  114 in total

1.  Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference.

Authors:  S Parrish; J Fleenor; S Xu; C Mello; A Fire
Journal:  Mol Cell       Date:  2000-11       Impact factor: 17.970

2.  Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.

Authors:  Veit Hornung; Margit Guenthner-Biller; Carole Bourquin; Andrea Ablasser; Martin Schlee; Satoshi Uematsu; Anne Noronha; Muthiah Manoharan; Shizuo Akira; Antonin de Fougerolles; Stefan Endres; Gunther Hartmann
Journal:  Nat Med       Date:  2005-02-20       Impact factor: 53.440

Review 3.  Strategies for silencing human disease using RNA interference.

Authors:  Daniel H Kim; John J Rossi
Journal:  Nat Rev Genet       Date:  2007-03       Impact factor: 53.242

4.  Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways.

Authors:  Dianne S Schwarz; György Hutvágner; Benjamin Haley; Phillip D Zamore
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

5.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

6.  Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor.

Authors:  Torgeir Holen; Mohammed Amarzguioui; Merete T Wiiger; Eshrat Babaie; Hans Prydz
Journal:  Nucleic Acids Res       Date:  2002-04-15       Impact factor: 16.971

7.  Activation of the interferon system by short-interfering RNAs.

Authors:  Carol A Sledz; Michelle Holko; Michael J de Veer; Robert H Silverman; Bryan R G Williams
Journal:  Nat Cell Biol       Date:  2003-08-24       Impact factor: 28.824

8.  Inhibition of influenza virus production in virus-infected mice by RNA interference.

Authors:  Qing Ge; Lily Filip; Ailin Bai; Tam Nguyen; Herman N Eisen; Jianzhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

9.  microRNA target predictions across seven Drosophila species and comparison to mammalian targets.

Authors:  Dominic Grün; Yi-Lu Wang; David Langenberger; Kristin C Gunsalus; Nikolaus Rajewsky
Journal:  PLoS Comput Biol       Date:  2005-06-24       Impact factor: 4.475

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more
  396 in total

1.  Pannexins in ischemia-induced neurodegeneration.

Authors:  Panagiotis Bargiotas; Antje Krenz; Sheriar G Hormuzdi; Dirk A Ridder; Anne Herb; Waleed Barakat; Silvia Penuela; Jakob von Engelhardt; Hannah Monyer; Markus Schwaninger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-06       Impact factor: 11.205

Review 2.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

3.  Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice.

Authors:  Sandra M Ocampo; Carolina Romero; Anna Aviñó; Joan Burgueño; Miguel A Gassull; Jordi Bermúdez; Ramon Eritja; Ester Fernandez; Jose C Perales
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

4.  SHAPE-directed discovery of potent shRNA inhibitors of HIV-1.

Authors:  Justin T Low; Stefanie A Knoepfel; Joseph M Watts; Olivier ter Brake; Ben Berkhout; Kevin M Weeks
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

Review 5.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

Review 6.  RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Authors:  Nicholas M Snead; John J Rossi
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

Review 7.  Minireview: Switching on progesterone receptor expression with duplex RNA.

Authors:  Bethany A Janowski; David R Corey
Journal:  Mol Endocrinol       Date:  2010-06-30

Review 8.  The emerging role of microRNAs in multiple sclerosis.

Authors:  Andreas Junker; Reinhard Hohlfeld; Edgar Meinl
Journal:  Nat Rev Neurol       Date:  2010-12-14       Impact factor: 42.937

9.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.

Authors:  Ryan L Boudreau; Ryan M Spengler; Beverly L Davidson
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 10.  siRNA-based therapeutic approaches for rheumatic diseases.

Authors:  Florence Apparailly; Christian Jorgensen
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.